Top

Published in:

Open Access 01-06-2019 | Metastasis | NON-THEMATIC REVIEW

Fugitives on the run: circulating tumor cells (CTCs) in metastatic diseases

Authors: Tania Mamdouhi, Julianne D. Twomey, K. Melodi McSweeney, Baolin Zhang

Published in: Cancer and Metastasis Reviews | Issue 1-2/2019

Abstract

The presence of circulating tumor cells (CTCs) in the bloodstream signals the existence of a tumor and denotes risk of metastatic spread. CTCs can be isolated and analyzed to monitor cancer progression and therapeutic response. However, CTC isolation devices have shown considerable variation in detection rates, limiting their use as a routine diagnostic and monitoring tool. In this review, we discuss recent advances in CTC detection methodologies and associated clinical studies. We provide perspective on the future direction of CTC isolation and molecular characterization towards developing reliable biomarkers that monitor disease progression or therapeutic response.

Seyfried, T. N., & Huysentruyt, L. C. (2013). On the origin of cancer metastasis. Critical Reviews in Oncogenesis, 18(1–2), 43–73.CrossRef

Moon, D. H., Lindsay, D. P., Hong, S., & Wang, A. Z. (2018). Clinical indications for, and the future of, circulating tumor cells. Advanced Drug Delivery Reviews, 125, 143–150. https://doi.org/10.1016/j.addr.2018.04.002.CrossRefPubMed

Marusyk, A., & Polyak, K. (2010). Tumor heterogeneity: causes and consequences. Biochimica et Biophysica Acta, 1805(1), 105–117. https://doi.org/10.1016/j.bbcan.2009.11.002.CrossRefPubMed

Administration, F. a. D. (2005). 510(k) substantial equivalence determination decision summary- Veridex, LLC (K050245).

Administration, F. a. D. (2010). Special 510(k) Device modification ODE review memorandum- Veridex, LLC (K103502).

Wit, S. d., Dalum, G. v., Lenferink, A. T. M., Tibbe, A. G. J., Hiltermann, T. J. N., Groen, H. J. M., van Rijn, C. J. M., & Terstappen, L. W. M. M. (2015). The detection of EpCAM+ and EpCAM– circulating tumor cells. Scientific Reports, 5, 12270. https://doi.org/10.1038/srep12270. https://www.nature.com/articles/srep12270#supplementary-information.CrossRefPubMedPubMedCentral

Noone, A., Howlader, N., Krapcho, M., Miller, D., Brest, A., Yu, M., et al. SEER Cancer Statistics Review, 1975–2015. Bethesda, MD: National Cancer Institute.

Donepudi, S., Reisinger, S. A., McGregor, J. R., Tharkar, S., Samlowski, S., Ostler, D., Shen, S., & Samlowski, W. E. (2013). Circulating tumor cell cultures as a predictive marker during salvage therapy of refractory Merkel cell carcinoma with chemotherapy and electron beam radiation. Journal of Cancer Therapy, 4(7), 5–1166. https://doi.org/10.4236/jct.2013.47135.CrossRef

Flaig, T. W., Wilson, S., van Bokhoven, A., Varella-Garcia, M., Wolfe, P., Maroni, P., Genova, E. E., Morales, D., & Lucia, M. S. (2011). The detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology, 78(4), 863–867. https://doi.org/10.1016/j.urology.2011.05.045.CrossRefPubMedPubMedCentral

10.

Li, Y., Gong, J., Zhang, Q., Lu, Z., Gao, J., Li, Y., Cao, Y., & Shen, L. (2016). Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. [clinical study]. British Journal of Cancer, 114, 138. https://doi.org/10.1038/bjc.2015.417 https://www.nature.com/articles/bjc2015417#supplementary-information.CrossRefPubMedPubMedCentral

11.

Reeh, M., Effenberger, K. E., Koenig, A. M., Riethdorf, S., Eichstädt, D., Vettorazzi, E., Uzunoglu, F. G., Vashist, Y. K., Izbicki, J. R., Pantel, K., & Bockhorn, M. (2015). Circulating tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal Cancer. Annals of Surgery, 261(6), 1124–1130. https://doi.org/10.1097/sla.0000000000001130.CrossRefPubMed

12.

Barrière, G., Tartary, M., & Rigaud, M. (2012). Epithelial mesenchymal transition: a new insight into the detection of circulating tumor cells. ISRN Oncology, 2012, 382010. https://doi.org/10.5402/2012/382010.CrossRefPubMedPubMedCentral

13.

Zhao, R., Cai, Z., Li, S., Cheng, Y., Gao, H., Liu, F., Wu, S., Liu, S., Dong, Y., Zheng, L., Zhang, W., Wu, X., & Yao, X. (2017). Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer. Oncotarget, 8(6), 9293–9302. https://doi.org/10.18632/oncotarget.14065.CrossRefPubMed

14.

Chen, W., Li, Y., Yuan, D., Peng, Y., & Qin, J. (2018). Practical value of identifying circulating tumor cells to evaluate esophageal squamous cell carcinoma staging and treatment efficacy. Thorac Cancer, 9(8), 956–966. https://doi.org/10.1111/1759-7714.12771.CrossRefPubMedPubMedCentral

15.

NCT01866202: study of circulating and tumor biomarkers in breast cancer patients (2013). ClinicalTrials.gov .

16.

NCT03156777: Application value of CTCs detection for advanced gastric cancer patients (2017). ClinicalTrials.gov .

17.

de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 14(19), 6302–6309. https://doi.org/10.1158/1078-0432.CCR-08-0872.CrossRefPubMed

18.

Larsson, A.-M., Jansson, S., Bendahl, P.-O., Levin Tykjaer Jörgensen, C., Loman, N., Graffman, C., Lundgren, L., Aaltonen, K., & Rydén, L. (2018). Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Research, 20(1), 48. https://doi.org/10.1186/s13058-018-0976-0.CrossRefPubMed

19.

Gonzalez-Rivera, M., Picornell, A. C., Alvarez, E. L., & Martin, M. (2016). A cross-sectional comparison of druggable mutations in primary tumors, metastatic tissue, circulating tumor cells, and cell-free circulating DNA in patients with metastatic breast Cancer: The MIRROR Study Protocol. JMIR Research Protocols, 5(3), e167. https://doi.org/10.2196/resprot.6024.CrossRefPubMedPubMedCentral

20.

Sundaresan, T. K., Sequist, L. V., Heymach, J. V., Riely, G. J., Jänne, P. A., Koch, W. H., et al. (2016). Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clinical Cancer Research, 22(5), 1103–1110. https://doi.org/10.1158/1078-0432.CCR-15-1031.CrossRefPubMed

21.

Millner, L. M., Linder, M. W., & Valdes, R. (2013). Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Annals of Clinical and Laboratory Science, 43(3), 295–304.PubMedPubMedCentral

22.

Shi, J., Li, Y., Liang, S., Zeng, J., Liu, G., Mu, F., Li, H., Chen, J., Liu, T., & Niu, L. (2016). Analysis of circulating tumor cells in colorectal cancer liver metastasis patients before and after cryosurgery. Cancer Biology & Therapy, 17(9), 935–942. https://doi.org/10.1080/15384047.2016.1210731.CrossRef

23.

Milojkovic Kerklaan, B., Pluim, D., Bol, M., Hofland, I., Westerga, J., van Tinteren, H., Beijnen, J. H., Boogerd, W., Schellens, J. H. M., & Brandsma, D. (2016). EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. Neuro-Oncology, 18(6), 855–862.CrossRef

24.

Qin, Z., Chen, J., Zeng, J., Niu, L., Xie, S., Wang, X., Liang, Y., Wu, Z., & Zhang, M. (2017). Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: a preliminary clinical study. Cancer Biology & Therapy, 18(5), 323–330. https://doi.org/10.1080/15384047.2017.1310346.CrossRef

25.

Brown, J. C., Troxel, A. B., Ky, B., Damjanov, N., Zemel, B. S., Rickels, M. R., Rhim, A. D., Rustgi, A. K., Courneya, K. S., & Schmitz, K. H. (2016). A randomized phase II dose-response exercise trial among colon cancer survivors: purpose, study design, methods, and recruitment results. Contemporary Clinical Trials, 47, 366–375. https://doi.org/10.1016/j.cct.2016.03.001.CrossRefPubMedPubMedCentral

26.

Cayrefourcq, L., Mazard, T., Joosse, S., Solassol, J., Ramos, J., Assenat, E., Schumacher, U., Costes, V., Maudelonde, T., Pantel, K., & Alix-Panabieres, C. (2015). Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Research, 75(5), 892–901. https://doi.org/10.1158/0008-5472.CAN-14-2613.CrossRefPubMed

27.

Abdallah, E. A., Fanelli, M. F., Souza e Silva, V., Machado Netto, M. C., Gasparini Junior, J. L., Araújo, D. V., Ocea, L. M., Buim, M. E., Tariki, M. S., Alves, V. D., Piana de Andrade, V., Dettino, A. L., Abdon Lopes de Mello, C., & Chinen, L. T. (2016). MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer. International Journal of Cancer, 139(4), 890–898. https://doi.org/10.1002/ijc.30082.CrossRefPubMed

28.

Gemenetzis, G., Groot, V. P., Yu, J., Ding, D., Teinor, J. A., Javed, A. A., Wood, L. D., Burkhart, R. A., Cameron, J. L., Makary, M. A., Weiss, M. J., He, J., & Wolfgang, C. L. (2018). Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective CLUSTER study. Annals of Surgery, 268(3), 408–420. https://doi.org/10.1097/SLA.0000000000002925.CrossRefPubMed

29.

Yang, L., Lv, Z., Xia, W., Zhang, W., Xin, Y., Yuan, H., Chen, Y., Hu, X., Lv, Y., Xu, Q., Weng, X., & Ni, C. (2018). The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. Clinical and Translational Oncology, 20(7), 912–921. https://doi.org/10.1007/s12094-017-1806-z.CrossRefPubMed

30.

Sefrioui, D., Blanchard, F., Toure, E., Basile, P., Beaussire, L., Dolfus, C., Perdrix, A., Paresy, M., Antonietti, M., Iwanicki-Caron, I., Alhameedi, R., Lecleire, S., Gangloff, A., Schwarz, L., Clatot, F., Tuech, J. J., Frébourg, T., Jardin, F., Sabourin, J. C., Sarafan-Vasseur, N., Michel, P., & di Fiore, F. (2017). Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. [molecular diagnostics]. British Journal of Cancer, 117, 1017–1025. https://doi.org/10.1038/bjc.2017.250 https://www.nature.com/articles/bjc2017250#supplementary-information.CrossRefPubMedPubMedCentral

31.

Ma, B., King, A. D., Leung, L., Wang, K., Poon, A., Ho, W. M., Mo, F., Chan, C. M. L., Chan, A. T. C., & Wong, S. C. C. (2017). Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer—a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. Annals of Oncology, 28(7), 1576–1581. https://doi.org/10.1093/annonc/mdx149.CrossRefPubMedPubMedCentral

32.

Hosokawa, M., Kenmotsu, H., Koh, Y., Yoshino, T., Yoshikawa, T., Naito, T., Takahashi, T., Murakami, H., Nakamura, Y., Tsuya, A., Shukuya, T., Ono, A., Akamatsu, H., Watanabe, R., Ono, S., Mori, K., Kanbara, H., Yamaguchi, K., Tanaka, T., Matsunaga, T., & Yamamoto, N. (2013). Size-based isolation of circulating tumor cells in lung Cancer patients using a microcavity Array system. PLoS One, 8(6), e67466. https://doi.org/10.1371/journal.pone.0067466.CrossRefPubMedPubMedCentral

33.

(FDA), F. a. D. A. (2004). 510(k) substantial equivalence determination decision summary - Veridex, LLC (K040898).

34.

Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., & Hayes, D. F. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine, 351(8), 781–791. https://doi.org/10.1056/NEJMoa040766.CrossRefPubMed

35.

Helissey, C., Berger, F., Cottu, P., Diéras, V., Mignot, L., Servois, V., Bouleuc, C., Asselain, B., Pelissier, S., Vaucher, I., Pierga, J. Y., & Bidard, F. C. (2015). Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. Cancer Letters, 360(2), 213–218. https://doi.org/10.1016/j.canlet.2015.02.010.CrossRefPubMed

36.

Moreno, J. G., Miller, M. C., Gross, S., Allard, W. J., Gomella, L. G., & Terstappen, L. W. M. M. (2005). Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology, 65(4), 713–718. https://doi.org/10.1016/j.urology.2004.11.006.CrossRefPubMed

37.

Cohen, S. J., Punt, C. J. A., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E., Miller, M. C., Doyle, G. V., Tissing, H., Terstappen, L. W. M. M., & Meropol, N. J. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(19), 3213–3221. https://doi.org/10.1200/JCO.2007.15.8923.CrossRefPubMed

38.

(2010). Circulating tumour cells. Nature Reviews Cancer, 11, 3. https://doi.org/10.1038/nrc3000.

39.

Agerbaek, M. O., Bang-Christensen, S. R., Yang, M. H., Clausen, T. M., Pereira, M. A., Sharma, S., et al. (2018). The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. Nature Communications, 9(1), 3279. https://doi.org/10.1038/s41467-018-05793-2.CrossRefPubMedPubMedCentral

40.

Goodman, O. B., Fink, L. M., Symanowski, J. T., Wong, B., Grobaski, B., Pomerantz, D., et al. (2009). Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiology Biomarkers; Prevention, 18(6), 1904. https://doi.org/10.1158/1055-9965.EPI-08-1173.CrossRef

41.

Heller, G., McCormack, R., Kheoh, T., Molina, A., Smith, M. R., Dreicer, R., Saad, F., de Wit, R., Aftab, D. T., Hirmand, M., Limon, A., Fizazi, K., Fleisher, M., de Bono, J. S., & Scher, H. I. (2018). Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials. Journal of Clinical Oncology, 36(6), 572–580. https://doi.org/10.1200/JCO.2017.75.2998.CrossRefPubMed

42.

Anido, U., Fita, M. J. J., Munielo-Romay, L., Pérez-Valderrama, B., Mellado, B., de Olza, M. O., Calvo, O. F., Castellano, D., Parra, E. M. F., Domenec, M., Hernando, S., Arija, J. A., Caballero, C., Duran, I., Campayo, M., & Climent, M. A. (2016). Phase II study of weekly cabazitaxel for ‘unfit’ metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis (SOGUG-CABASEM Trial). Annals of Oncology, 27(suppl_6), 753P–753P. https://doi.org/10.1093/annonc/mdw372.37.CrossRef

43.

NCT02538432: phase II trial of EP4 receptor antagonist, AAT-007 (RQ-07; CJ-023,423) in advanced solid tumors (2015). ClinicalTrials.gov.

44.

Eigl, B. J., Chi, K., Tu, D., Hotte, S. J., Winquist, E., Booth, C. M., Canil, C., Potvin, K., Gregg, R., North, S., Zulfiqar, M., Ellard, S., Ruether, J. D., le, L., Kakumanu, S. A., Salim, M., Allan, A. L., Feilotter, H., Theis, A., & Seymour, L. (2018). A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. Oncotarget, 9(8), 8155–8164. https://doi.org/10.18632/oncotarget.24263.CrossRefPubMedPubMedCentral

45.

Smerage, J. B., Barlow, W. E., Hortobagyi, G. N., Winer, E. P., Leyland-Jones, B., Srkalovic, G., Tejwani, S., Schott, A. F., O'Rourke, M. A., Lew, D. L., Doyle, G. V., Gralow, J. R., Livingston, R. B., & Hayes, D. F. (2014). Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. Journal of Clinical Oncology, 32(31), 3483–3489. https://doi.org/10.1200/jco.2014.56.2561.CrossRefPubMedPubMedCentral

46.

Lianidou, E. S., Markou, A., & Strati, A. (2012). Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. Cancer and Metastasis Reviews, 31(3), 663–671. https://doi.org/10.1007/s10555-012-9366-8.CrossRefPubMed

47.

Wang, D., Liu, X., Hsieh, B., Bruce, R., Somlo, G., Huang, J., & Sambucetti, L. (2015). Exploring glycan markers for immunotyping and precision-targeting of breast circulating tumor cells. Archives of Medical Research, 46(8), 642–650. https://doi.org/10.1016/j.arcmed.2015.11.007.CrossRefPubMedPubMedCentral

48.

NCT03366116: 5-aza-4′-Thio-2′-deoxycytidine (Aza-TdC) in people with advanced solid tumors (2017). ClinicalTrials.gov.

49.

Pantel, K., & Alix-Panabières, C. (2017). Circulating tumour cells and cell-free DNA in gastrointestinal cancer. Nature Reviews Gastroenterology &Amp; Hepatology, 14, 73–74. https://doi.org/10.1038/nrgastro.2016.198.CrossRef

50.

Magbanua, M. J. M., & Park, J. W. (2014). Advances in genomic characterization of circulating tumor cells. Cancer and Metastasis Reviews, 33(2), 757–769. https://doi.org/10.1007/s10555-014-9503-7.CrossRefPubMed

51.

Chen, X. X., & Bai, F. (2015). Single-cell analyses of circulating tumor cells. In Cancer biol med (Vol. 12, pp. 184–192, Vol. 3).

52.

Sergeant, G., van Eijsden, R., Roskams, T., Van Duppen, V., & Topal, B. (2012). Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. BMC Cancer, 12, 527–527. https://doi.org/10.1186/1471-2407-12-527.CrossRefPubMedPubMedCentral

53.

Fehm, T., Müller, V., Aktas, B., Janni, W., Schneeweiss, A., Stickeler, E., Lattrich, C., Löhberg, C. R., Solomayer, E., Rack, B., Riethdorf, S., Klein, C., Schindlbeck, C., Brocker, K., Kasimir-Bauer, S., Wallwiener, D., & Pantel, K. (2010). HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Research and Treatment, 124(2), 403–412. https://doi.org/10.1007/s10549-010-1163-x.CrossRefPubMed

54.

Polasik, A., Schramm, A., Friedl, T. W. P., Rack, B. K., Trapp, E. K., Fasching, P. A., Taran, F. A., Hartkopf, A. D., Schneeweiss, A., Mueller, V., Aktas, B., Pantel, K., Meier-Stiegen, F., Wimberger, P., Janni, W., & Fehm, T. N. (2016). The DETECT study concept: individualized therapy of metastatic breast cancer. Journal of Clinical Oncology, 34(15_suppl), TPS634–TPS634. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS634.CrossRef

55.

Hainsworth, J. D., Murphy, P. B., Alemar, J. R., Daniel, B. R., Young, R. R., & Yardley, D. A. (2016). Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: Lack of response to HER2-targeted therapy. Breast Cancer Research and Treatment, 160(1), 41–49. https://doi.org/10.1007/s10549-016-3969-7.CrossRefPubMed

56.

Bidard, F. C., Cottu, P., Dubot, C., Venat-Bouvet, L., Lortholary, A., Bourgeois, H., et al. (2017). 117PAnti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial. Annals of Oncology, 28(suppl_5), mdx363.033. https://doi.org/10.1093/annonc/mdx363.033.CrossRef

57.

Salanti, A., Clausen, T. M., Agerbaek, M. O., Al Nakouzi, N., Dahlback, M., Oo, H. Z., et al. (2015). Targeting human cancer by a glycosaminoglycan binding malaria protein. Cancer Cell, 28(4), 500–514. https://doi.org/10.1016/j.ccell.2015.09.003.CrossRefPubMedPubMedCentral

58.

Caixeiro, N. J., Kienzle, N., Lim, S. H., Spring, K. J., Tognela, A., Scott, K. F., de Souza, P., & Becker, T. M. (2014). Circulating tumour cells—a bona fide cause of metastatic cancer. Cancer and Metastasis Reviews, 33(2), 747–756. https://doi.org/10.1007/s10555-014-9502-8.CrossRefPubMed

59.

Bünger, S., Zimmermann, M., & Habermann, J. K. (2015). Diversity of assessing circulating tumor cells (CTCs) emphasizes need for standardization: a CTC guide to design and report trials. Cancer and Metastasis Reviews, 34(3), 527–545. https://doi.org/10.1007/s10555-015-9582-0.CrossRefPubMed

Title: Fugitives on the run: circulating tumor cells (CTCs) in metastatic diseases
Authors: Tania Mamdouhi
Julianne D. Twomey
K. Melodi McSweeney
Baolin Zhang
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Metastasis
Biomarkers
Published in: Cancer and Metastasis Reviews / Issue 1-2/2019
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-019-09795-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2019

Cause and effect of microenvironmental acidosis on bone metastases

Correction to: Tumor pH and metastasis: a malignant process beyond hypoxia

Correction to: mTOR co-targeting strategies for head and neck cancer therapy

Preface

Acidosis and proteolysis in the tumor microenvironment

The Warburg metabolism fuels tumor metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer